PRTN3 and anti-neutrophil cytoplasmic antibody-associated vasculitis: The percentage of the latter ranges from 0–100%, is genetically determined and stable in a given individual, is significantly higher in AAV patients than in healthy controls, responds stronger to PR3-ANCA in vitro, and is associated with worse disease outcome14, 15, 16, 17, 18, 19.